Monthly Archives: May 2012

Research and Markets: North America Neurology Devices Market Outlook to 2018 – Interventional Neurology, Neurological …

Posted on by

DUBLIN--(BUSINESS WIRE)--

Dublin - Research and Markets (http://www.researchandmarkets.com/research/prl69j/north_america_neur) has announced the addition of GlobalData's new report "North America Neurology Devices Market Outlook to 2018 - Interventional Neurology, Neurological Diagnostic Equipment, Neurostimulation Devices and Others" to their offering.

GlobalData's new report, North America Neurology Devices Market Outlook to 2018 - Interventional Neurology, Neurological Diagnostic Equipment, Neurostimulation Devices and Others provides key market data on the North America Neurology Devices market - Canada and United States. The report provides value (USD million) data for all the market categories - CSF Management, Interventional Neurology, Neurological Diagnostic Equipment, Neurostimulation Devices, Neurosurgical Products and Radiosurgery. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants.

Scope:

- Countries covered include Canada and United States.

- Market size and company share data for Neurology Devices market categories - CSF Management, Interventional Neurology, Neurological Diagnostic Equipment, Neurostimulation Devices, Neurosurgical Products and Radiosurgery.

- Annualized market revenues (USD million) data for each of the market categories in each of the country. Data from 2004 to 2011, forecast forward for 7 years to 2018.

- 2011 company shares and distribution shares data for each of the market categories and countries.

- Global corporate-level profiles of key companies operating within the North America Neurology Devices market..

Companies Mentioned:

The rest is here:
Research and Markets: North America Neurology Devices Market Outlook to 2018 - Interventional Neurology, Neurological ...

Research and Markets: Saudi Arabia Neurology Devices Market Outlook to 2018 – Interventional Neurology, Neurological …

Posted on by

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/mbvxrd/saudi_arabia_neuro) has announced the addition of GlobalData's new report "Saudi Arabia Neurology Devices Market Outlook to 2018 - Interventional Neurology, Neurological Diagnostic Equipment, Neurostimulation Devices and Others" to their offering.

This new report provides key market data on the Saudi Arabia Neurology Devices market. The report provides value (USD million), volume (units) and average price (USD) data for each segment and sub-segment within six market categories - CSF Management, Interventional Neurology, Neurological Diagnostic Equipment, Neurostimulation Devices, Neurosurgical Products and Radiosurgery. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants with information on company financials and pipeline products, wherever available.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

- Market size and company share data for Neurology Devices market categories - CSF Management, Interventional Neurology, Neurological Diagnostic Equipment, Neurostimulation Devices, Neurosurgical Products and Radiosurgery.

- Annualized market revenues (USD million), volume (units) and average price (USD) data for each of the segments and sub-segments within six market categories. Data from 2004 to 2011, forecast forward for 7 years to 2018.

- 2011 company shares and distribution shares data for each of the six market categories.

- Global corporate-level profiles of key companies operating within the Saudi Arabia Neurology Devices market.

- Key players covered include Medtronic, Inc., Nihon Kohden Corporation, DePuy, Inc., Natus Medical Incorporated, B. Braun Melsungen AG, CareFusion Corporation and others.

Here is the original post:
Research and Markets: Saudi Arabia Neurology Devices Market Outlook to 2018 - Interventional Neurology, Neurological ...

Nansulate® Energy Saving Coatings by Industrial Nanotech, Inc. Featured in Sustainable Manufacturing Publications

Posted on by

NAPLES, Fla.--(BUSINESS WIRE)--

Industrial Nanotech, Inc. (Pink Sheets:INTK), an emerging global leader in nanotechnology based energy saving and sustainable solutions announced today that their patented Nansulate coatings for equipment and building energy efficiency have been featured in two recent green/sustainable manufacturing focused publications. The current May/June issue of Green Manufacturer Magazine contains a Nansulate customer case study for reduction of exterior oven surface temperature and improved safety, and their article about using nanocoatings to improve building envelope energy efficiency is published online at SustainablePlant.com. Both entities are focused on green and sustainable manufacturing and facility solutions.

Nansulate coatings continue to establish a solid reputation among both international and U.S. manufacturers for valuable and affordable energy saving and protective benefits, stated Francesca Crolley, V.P. Business Development for Industrial Nanotech, Inc. We are fortunate to be able to provide a unique and effective technology that pays for itself in a short period of time, helping corporations meet their sustainability objectives with a product that is also an excellent investment. The case study highlighted in Green Manufacturer Magazine is an excellent example of the combination of important benefits that our coatings provide. In addition to reducing the energy consumption of ovens used for heat block blasting, our coating also reduced the exterior surface temperature from 168F to between 100F-115F, which provided significant safety benefits. These articles featured in two well known publications with a commercial and manufacturing audience, focused on sustainability and reduction of energy consumption, are a good indicator that the track record of performance our coatings have built up since 2004 is taking a hold in multiple industries, and Industrial Nanotech and Nansulate are being looked at as a source for high quality, innovative energy saving products that provide short term payback for applications of all types.

About Nansulate

Nansulate is the Company's patented product line of award winning, specialty coatings containing a nanotechnology based material and which are well-documented to provide the combined performance qualities of thermal insulation, corrosion prevention, resistance to mold growth, fire resistance, chemical resistance and lead encapsulation in an environmentally safe, water-based, coating formulation. The Nansulate Product Line includes industrial, residential, agricultural and solar thermal insulation coatings. Additional information about the Company and its products can be found at their websites, (www.inanotk.com) and (www.nansulate.com). Blog: http://www.nansulate.com/nanoblog, Twitter: http://www.twitter.com/NanoPioneer, Facebook: http://www.facebook.com/Nansulate.

About Industrial Nanotech Inc.

Industrial Nanotech Inc. is a global nanoscience solutions and research leader and member of the U.S. Green Building Council. The Company develops and commercializes new and innovative applications for sustainable nanotechnology which are sold worldwide.

Safe Harbor Statement

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties including, but not limited to, the impact of competitive products, the ability to meet customer demand, the ability to manage growth, acquisitions of technology, equipment, or human resources, the effect of economic and business conditions, and the ability to attract and retain skilled personnel. The Company is not obligated to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.

Read the original here:
Nansulate® Energy Saving Coatings by Industrial Nanotech, Inc. Featured in Sustainable Manufacturing Publications

DNA strands create tiniest Smileys

Posted on by

Harvard University scientists on Wednesday said they had created Smileys, Chinese characters and card-game symbols at scales of billionths of a metre using strands of DNA.

The feat marks the next step in "DNA origami" in which the molecule that provides the genetic code for life is used as a building block at the nanoscale, with potential outlets in engineering and medicine.

DNA is like a twisted ladder with double "rungs" of chemicals which interlock.

By unzipping the ladder and cutting it lengthwise, researchers can create a stretch with a set of single rungs that can partner up with a matching strand.

This is the characteristic harnessed by a team led by Peng Yin of Harvard's Wyss Institute for Biologically Inpired Engineering.

Reporting in the British journal Nature, the team showed off short lengths of DNA, each 42 "rungs" long, that interlocked with complementary stretches of the molecule.

Like Lego tiles, the strands could be programmed to assemble themselves into specific shapes.

To demonstrate the method, the team made a molecular picture featuring 107 designs, from emoticons, Chinese characters, numbers and letters from the Latin alphabet.

The canvas is a rectangle measuring 64 nanometres by 103 nanometres, with 310 pixels.

Scientists have been interested in nanoscale shapes for more than 20 years, and have progressively moved from two dimensional to three dimensional successes.

View original post here:
DNA strands create tiniest Smileys

Ross University School of Medicine Signs Affiliation Agreement to Enhance Clinical Education with Kern Medical Center

Posted on by

NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--

Ross University School of Medicine (RUSM) and Kern Medical Center (KMC) in Bakersfield, Calif. today announced a 10-year affiliation agreement to allocate, on an annual basis, a significant number of core clinical rotation slots to RUSM students. The affiliation, which will allow RUSM students placed at KMC to complete all of their third-year clinical rotations there over 48 consecutive weeks, is the largest clinical affiliation arrangement in RUSMs history.

Kern Medical Center, established in 1867, is a 222-bed acute care teaching hospital owned and operated by the County of Kern. As the major healthcare provider serving a community of approximately 650,000 residents, KMC is an integral part of the local community. KMC provides care for more than 16,000 inpatients annually, and experiences 43,000 Emergency Room visits per year. In addition, KMCs three federally qualified health centers serve 100,000 outpatients per year.

This is a landmark development for Ross for many reasons, especially for the opportunity to work closely with an institution that shares our commitment to serving the local community, said Joseph Flaherty, MD, dean and chancellor of RUSM. RUSM students who complete their rotations at Kern will not only benefit from learning from Kerns great faculty and residents, but also gain an appreciation for the important role these community hospitals and their physicians play in the lives of local families.

All of KMCs core residency programsInternal Medicine, Family Medicine, Surgery, Obstetrics & Gynecology, and Psychiatryare accredited by the Accreditation Council on Graduate Medical Education (ACGME). KMCs affiliations with the University of California at Los Angeles, David Geffen School of Medicine and University of California, Irvine, School of Medicine ensure a significant depth and breadth of teaching resources, in addition to KMCs 65 full-time faculty physicians.

Paul Hensler, FACHE, chief executive officer at KMC, said that RUSM is a partner that shares Kern Medical Centers academic vision. The affiliation, he said, is geared to looking after the long-term sustainability of the local physician workforce. California in general and the San Joaquin Valley in particular are medically underserved. We believe that building a robust working relationship with RUSM will enable us to provide a superior clinical rotation experience with the potential to attract physicians to our community, said Hensler.

Enrique Fernandez, MD, senior associate dean for clinical sciences at RUSM, said the new affiliation is great news for current students, seventeen percent of whom are from California. Many of our students have already set a goal of returning to their home communities to practice medicine. This partnership will enable many of them to complete their clinical clerkships in California as well, he said.

As part of the agreement, RUSM and KMC will offer scholarships to accepted RUSM students from Kern County, via the Kern Medical Center Foundation.

About Ross University School of Medicine

Ross University School of Medicine (RUSM) was founded in 1978 and is a provider of medical education offering a Doctor of Medicine degree program. Students begin their foundational studies in Dominica, West Indies, and complete their clinical training in teaching hospitals throughout the United States. RUSM graduates obtain more US residencies than graduates of any other medical school in the world.

Read more here:
Ross University School of Medicine Signs Affiliation Agreement to Enhance Clinical Education with Kern Medical Center

Maybe medical school debt isn’t the problem

Posted on by

The high cost of medical school often gets tossed around as a key reason why doctors dont go into primary care jobs, instead choosing specialties such as radiology and surgery that prove more lucrative. When physicians graduate with an average of $161,290 in debt, its hard (Melissa Cannarozzi/The Washington Post) to see money not factoring into career decisions.

While this narrative makes sense, theres one major flaw: It doesnt seem to be true. Aaron Carroll flags a story in the San Francisco-area Bay Citizen, where a local health-care authority established a loan forgiveness program. If doctors committed to practicing primary care in the area, for at least four years, all of their loans would be forgiven.

The program has been around for a decade now and no one has signed up. Not a single doctor has volunteered for the opportunity to have all of their educational debt relieved. In San Mateo County, at least, debt didnt seem to be the big obstacle for doctors pursuing primary care careers.

This doesnt seem to be specific to one area of California. National data on medical student debt find that those with a high debt burden are actually more likely to go into the less lucrative primary care fields than doctors who hold no loans at all.

For private schools, odds of choosing primary care increases as debt increases, with those having no debt (and no scholarships) less likely to choose primary care, researchers at the Robert Graham Center concluded in a 2009 report.

Why do those with a higher-debt burden go into lower paying medical fields? Debt-free doctors, the thinking goes, come from higher socioeconomic backgrounds and tend to have higher expectations for their eventual salary.

For those who come from a less advantaged background, and do take out loans, the calculus might be a bit different. You have people who are willing to tolerate up to $200,000 in debt to become a doctor, Robert Phillips, director of the Robert Graham Center, said in a recent interview. To him, it suggests that doctors who have already made a huge financial commitment to becoming a physician arent as concerned with their eventual salary.

Here is the original post:
Maybe medical school debt isn’t the problem

Seg _ 1 -Suvarnanews – Something Special – Reproductive System – 29 May 12 – Suvarna News – Video

Posted on by

30-05-2012 05:31 Suvarna News 24X7 - 29 May 2012 In the human reproductive process, two kinds of sex cells, or gametes, are involved. The male gamete, or sperm, and the female gamete, the egg or ovum, meet in the female's reproductive system to create a new individual. Both the male and female reproductive systems are essential for reproduction.

Original post:
Seg _ 1 -Suvarnanews - Something Special - Reproductive System - 29 May 12 - Suvarna News - Video

Seg _ 2 -Suvarnanews – Something Special – Reproductive System – 29 May 12 – Suvarna News – Video

Posted on by

30-05-2012 05:35 Suvarna News 24X7 - 29 May 2012 In the human reproductive process, two kinds of sex cells, or gametes, are involved. The male gamete, or sperm, and the female gamete, the egg or ovum, meet in the female's reproductive system to create a new individual. Both the male and female reproductive systems are essential for reproduction.

Read more from the original source:
Seg _ 2 -Suvarnanews - Something Special - Reproductive System - 29 May 12 - Suvarna News - Video

Genes Predict if Medication Can Help You Quit Smoking

Posted on by

Newswise The same gene variations that make it difficult to stop smoking also increase the likelihood that heavy smokers will respond to nicotine-replacement therapy and drugs that thwart cravings, a new study shows.

The research, led by investigators at Washington University School of Medicine in St. Louis, will appear online May 30 in the American Journal of Psychiatry.

The study suggests it may one day be possible to predict which patients are most likely to benefit from drug treatments for nicotine addiction.

Smokers whose genetic makeup puts them at the greatest risk for heavy smoking, nicotine addiction and problems kicking the habit also appear to be the same people who respond most robustly to pharmacologic therapy for smoking cessation, says senior investigator Laura Jean Bierut, MD, professor of psychiatry. Our research suggests that a persons genetic makeup can help us better predict who is most likely to respond to drug therapy so we can make sure those individuals are treated with medication in addition to counseling or other interventions.

For the new study, the researchers analyzed data from more than 5,000 smokers who participated in community-based studies and more than 1,000 smokers in a clinical treatment study. The scientists focused on the relationship between their ability to quit smoking successfully and genetic variations that have been associated with risk for heavy smoking and nicotine dependence.

People with the high-risk genetic markers smoked an average of two years longer than those without these high-risk genes, and they were less likely to quit smoking without medication, says first author Li-Shiun Chen, MD, assistant professor of psychiatry at Washington University. The same gene variants can predict a persons response to smoking-cessation medication, and those with the high-risk genes are more likely to respond to the medication.

In the clinical treatment trial, individuals with the high-risk variants were three times more likely to respond to drug therapy, such as nicotine gum, nicotine patches, the antidepressant buproprion and other drugs used to help people quit.

Tobacco use is the leading cause of preventable illness and death in the United States and a major public health problem worldwide. Cigarette smoking contributes to the deaths of an estimated 443,000 Americans each year. Although lung cancer is the leading cause of smoking-related cancer death among both men and women, tobacco also contributes to other lung problems, many other cancers and heart attacks.

Bierut and Chen say that the gene variations they studied are not the only ones involved in whether a person smokes, becomes addicted to nicotine or has difficulty quitting. But they contend that because the same genes can predict both heavy smoking and enhanced response to drug treatment, the genetic variants are important to the addiction puzzle.

Its almost like we have a corner piece here, Bierut says. Its a key piece of the puzzle, and now we can build on it. Clearly these genes arent the entire story other genes play a role, and environmental factors also are important. But weve identified a group thats responding to pharmacologic treatment and a group thats not responding, and thats a key step in improving, and eventually tailoring, treatments to help people quit smoking.

See more here:
Genes Predict if Medication Can Help You Quit Smoking

UGA chemistry professors awarded $1.5 million to conduct energy-related research

Posted on by

If you want to increase your cars gas mileage or build a more powerful handheld electronic device, dont bend steel or slice silicon chips. Manipulate nanomaterials and molecules instead.

Funded by the U.S. Department of Energy, two University researchers will pursue more efficient methods of energy transmission and storage that involve maneuvering microscopic particles. Tina Salguero and Gary Douberly, assistant professors of chemistry in the UGA Franklin College of Arts and Sciences, will each receive $750,000 for five years from the DOEs Office of Science Early Career Research Program for energy-related projects.

Gary Douberly

This is tremendous news that continues the very strong performance of the chemistry faculty in recent years, said UGA President Michael F. Adams. At a time when this country faces serious questions about the future of its energy supply, research focused on energy efficiency is a national priority. I am proud that Drs. Salguero and Douberly are being supported by the Department of Energy in their groundbreaking research.

Salguero will focus on increasing the energy capacity for compact electrical devices while Douberly looks to new technologies to improve fuel efficiency.

Tina Salguero

Our efforts will develop the first synthetic methods for creating these types of nanosheets, and the characterization studies will show whether they retain their important dielectric properties, she said.

Salguero plans to develop methodologies for preparing ceramics in nanosheet form and to gauge their properties. She will also test two ways to process the nanosheets-first via inkjet printing of liquid crystalline nanosheets and second by mechanically assembling alternating layers of conducting and non-conducting materials to build up dense, hybrid nanosheet structures capable of greater energy storage.

Devices using this technology would have an energy density far exceeding anything possible today, Salguero said. Ceramic nanosheets could enable technological wonders like handheld high-power lasers and mobile electromagnetic launchers.

Douberly will use his funding to capture short-lived molecules and free radicals-highly reactive molecules-that arise during engine ignition. He will use a method called helium nanodroplet isolation to hold molecule groups-or species-that form for brief moments during combustion. Douberly will capture the molecules inside drops of super-cooled liquid helium and subject them to infrared laser spectroscopy to determine their molecular structure and their unique combinations of electromagnetic radiation wavelengths, or spectroscopic signatures.

Read more here:
UGA chemistry professors awarded $1.5 million to conduct energy-related research

Coutinho: Great Team Chemistry Has Fueled Mets’ Success

Posted on by

(credit: Al Bello/Getty Images)

By Rich Coutinho More Columns

Over the course of a long baseball season, there will be ups and downs, injuries curtailing winning streaks. But allsuccessful teams have one constant: leadership.

Chemistry in the clubhouse.

It can extend winning streaks and snap losing streaks. The Mets have great chemistry, and thats been been of the biggest reasons New York sits in second place in the competitive NL East.

They came into the season with all the experts saying they had too many holes, not enough depth and inferior starting pitching. The fans, for the most part, bought that snow job hook, line and sinker. Thats all they heard from the media. But make no mistake about it the Metsare serious playoff contenders 50 games into the season.

Thatsright Iused the P word.

You want leadership? There are no better in this sport than Johan Santana and David Wright, who lead the right way. They dont do it for the world to see by throwing over a table or scolding a teammate. They do it by example. The younger players see Wright and Santana are the first to arrive, embrace their responsibility to the media, and compete.

Terry Collins deserves a bunch of credit for motivating these players, and so does his coaching staff. Consider the job Tim Teufel has done with Daniel Murphy at second base. Murphy will never be confused with Bill Mazeroski around the bag, but he has been serviceable due in large part to the amount of work he and Teufel put in during the offseason. And that has kept his potent bat in the lineup.

The numbers dont lie. The Metsare 16-10 at Citi Field and 12-12 on the road, the formula for a winning season. Theyre also 15-8 against the National League East, which is why they are only one and half games from the top spot in the division. What they lack in talent they make up for in resiliency, and that speaks to team chemistry. I have never been around a team that pulls for each other like this team even when one player is in competition with another for playing time.

Read the rest here:
Coutinho: Great Team Chemistry Has Fueled Mets’ Success

US Chemistry Nobel Laureate to arrive in Tehran

Posted on by

Source: ISNA

Chemistry Nobel Laureate Peter Agre, Professor and Director of the Johns Hopkins Malaria Research Institute and Dr. Norman Neureiter the Acting Director of Center for Science, Technology & Security Policy of American Association for the Advancement of Science and the first US scientific ambassador to Europe are to arrive in Tehran in coming days.

Dr, Norman Neureiter is scheduled to deliver a lecture on "International Cooperation on Science and Technology Diplomacy, Opportunities and Challenges in the 21 Century" in Iranian Shahid Beheshti University on June 11.

Also Professor Peter Agre will attend the ceremony.

Peter Agre born on January 30, 1949 is an American medical doctor, professor, and molecular biologist who was awarded the 2003 Nobel Prize in Chemistry (which he shared with Roderick MacKinnon for his discovery of aquaporins. Aquaporins are water-channel proteins that move water molecules through the cell membrane.

In February 2009, Peter Agre was inducted as the 163rd president of the American Association for the Advancement of Science (AAAS), the nation's largest scientific organization. He is currently a professor at Johns Hopkins University.

He received his B.A. from Augsburg College in Minneapolis and his M.D. in 1974 from the Johns Hopkins University School of Medicine in Baltimore, Maryland.

From 1975 to 1978 he completed his clinical training in Internal Medicine at Case Western Reserve University's Case Medical Center under Charles C.J. Carpenter.

He served as the Vice Chancellor for science and technology at Duke University Medical Center in Durham, North Carolina, where he guided the development of Duke's biomedical research.

Read the original:
US Chemistry Nobel Laureate to arrive in Tehran

Green Chemistry Carving a Bigger Role in Sustainable Manufacturing

Posted on by

Credit: Nathan Walker, CC BY 2.0

Dave Kepler, chief sustainability officer at Dow Chemical Co., believes that to meet the demands of a burgeoning population, we will need more sustainable products and infrastructure in short, a more sustainable economy.

Writing for GreenBiz, Kepler says sustainable chemistry will play a key role in meeting the increasing demands for material goods in an environment of tight resources and energy supply. He writes that more than 95 percent of manufactured goods rely on certain chemical building blocks somewhere in their value chains that is, basic chemicals from which other chemicals get made. For that reason, integrating sustainability and green chemistry concepts sustainable chemistry as a building block is a vitally important part of building a more sustainable economy.

Dows sustainability strategy includes a set of four pillars of sustainable chemistry:

Kepler says Dows green chemistry efforts have led to products such as roofing shingles with integrated photovoltaics that make harnessing the power of the sun affordable, advanced lithium-ion batteries for improved hybrid and electric vehicle efficiency, corn seed traits that increase crop productivity and a joint venture with Mitsui in Brazil to make plastics from sugar cane.

That last detail making plastics from sugar cane is intriguing, especially in light of a recent article, Status Report: Green Chemistry for Polymers, by Sally Humphreys of research firm Applied Market Information. The article discusses a wide variety of efforts in the plastics industry to employ biological substitutes for fossil fuels as feedstocks for producing polymers.

Humphreys also highlights efforts in Brazil to produce plastics from sugar cane:

The Brazilian sugar cane industry is the largest in the world. [Brazilian petrochemical firm] Braskem has used this sugar as a source of feedstock to make its green polyethylene and polypropylene with current capacities at 200 and 30 kilotonnes per year respectively. 86.5 tons of sugar cane gives 7,200 liters of ethanol and 3 tonnes of polyethylene. Brazil has vast areas of arable land that could be used to develop this industry and Braskem is studying all aspects including ways to increase yield.

Sugar cane field in Brazil. Credit: Maria Hsu, CC BY 2.0

As another example, Ford Motor Co. has been testing the use of a soy polyol-based polyurethane foam, a bio-thermoplastic urethane (TPU) developed from renewable sources.

See the original post:
Green Chemistry Carving a Bigger Role in Sustainable Manufacturing

2012 BIO International Convention Buzz of BIO Winner Announced

Posted on by

WASHINGTON--(BUSINESS WIRE)--

The Biotechnology Industry Organization (BIO) is pleased to announce the Pipelines of Promise Buzz of BIO winner for the 2012 BIO International Convention is Deuteria Pharmaceuticals, Inc., a virtual biotechnology company based in Boston, Mass. and founded in 2010.

The Buzz of BIO competition is an exciting opportunity for emerging companies to capture the spotlight and level the playing field a bit amongst their more established industry peers, said Jim Greenwood, President and CEO of the Biotechnology Industry Organization. As a Buzz winner, this company will now enter the Convention with a heightened sense of anticipation and buzz, allowing for endless partnering opportunities.

More on the Pipelines of Promise Buzz of BIO Winner:

As an emerging company with a pioneering approach to therapeutics, Deuteria Pharmaceuticals is pleased to be recognized as the Pipeline of Promise company by the premier conference in the biotechnology industry. This recognition from BIO 2012 provides and strengthens the visibility of Deuteria Pharmaceuticals, said Dr. Sheila DeWitt, President, Deuteria Pharmaceuticals, Inc.

As the winner, Deuteria Pharmaceuticals will receive complimentary registration to the Convention, held June 18 -21, 2012 in Boston, MA, with partnering, and a 15-minute Company Presentation in the BIO Business Forum. To learn more about what makes Deuteria Pharmaceuticals the Buzz of BIO, watch their presentation in the Business Forum, Tuesday, June 19th at 10:15 a.m. (Patriots Room), and find them in the One-on-One Partnering System to schedule a 1x1 partnering meeting.

The BIO Business Forum has grownover thepast eleven years to become theindustry's largest partnering event, hosting a record breaking 21,000+ partnering meetings in 2011. Powered byBIO's One-on-One Partnering System, the Business Forum fosters the opportunity for companies toinitiate business contacts in a friendly environment and schedule meetings prior to theconference. To take advantage of partnering, please visit here.

The BIO Business Forum also hosts over 160 company presentations, which by participating, will allow the Buzz of BIO winners to increase visibility, attract more partners and pitch their company objectives to a global audience representing over sixty countries and various industry investors, research analysts, policy makers and other business development executives.

The BIO International Convention will highlight the latest trends and the newest opportunities for executives, investors, scientists, policy leaders, and media from around the world. Speakers at the sessions will share breakthroughs in medicine, diagnostics, the environment, energy production, business operations, financing, partnerships, policy issues and food and agriculture. For registration, conference agenda and exhibitor information, visit 2012 BIO International Convention.

Upcoming BIO Events

Read the original here:
2012 BIO International Convention Buzz of BIO Winner Announced

Puma Biotechnology to Present at Jefferies Healthcare Conference

Posted on by

LOS ANGELES--(BUSINESS WIRE)--

Puma Biotechnology, Inc. (PBYI), a development stage biopharmaceutical company, announced that Alan H. Auerbach, its Chairman, Chief Executive Officer, President and Founder, will present an overview of the Company at 9:30 a.m. EDT on Wednesday, June 6, at the Jefferies 2012 Global Healthcare Conference.

A live webcast will be available on the Companys website at http://www.pumabiotechnology.com. The presentation will be archived on the website and available for 30 days.

About Puma Biotechnology

Puma Biotechnology, Inc. is a development stage biopharmaceutical company that acquires and develops innovative products for the treatment of various forms of cancer. The Company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. The Company is initially focused on the development of PB272 (oral neratinib), a potent irreversible tyrosine kinase inhibitor, for the treatment of patients with HER2 positive metastatic breast cancer.

Further information about Puma Biotechnology can be found at http://www.pumabiotechnology.com.

Forward-Looking Statements:

This press release contains forward-looking statements that involve risks and uncertainties that could cause the Companys actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors, which include, but are not limited to, the risk factors disclosed in the periodic reports filed by the Company with the Securities and Exchange Commission from time to time. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company assumes no obligation to update these forward-looking statements, except as required by law.

Continue reading here:
Puma Biotechnology to Present at Jefferies Healthcare Conference

Memoir tracks the life, decline and death of a family farm

Posted on by

Public release date: 30-May-2012 [ | E-mail | Share ]

Contact: Diana Yates diya@illinois.edu 217-333-5802 University of Illinois at Urbana-Champaign

CHAMPAIGN, Ill. There is no sentimentality in Robert Switzer's modestly titled new book, "A Family Farm: Life on an Illinois Dairy Farm." Switzer, an emeritus professor of biochemistry at the University of Illinois, begins with a quote (from Victor Davis Hanson's own book on farming) that "the American yeoman farmer is doomed," and describes the internal and external forces that led to the demise of his family's farm in northwest Illinois.

The story of the Allison-Switzer farm (named for Switzer's maternal grandparents, who bought the 121-acre property in 1916, and his father and mother, who took it over after her parents retired in 1946) is just one of millions of such stories, Switzer writes.

"In 1900, 42 percent of the U.S. population lived on farms; by 1990 that number had dwindled to less than 2 percent," he says in the book's prologue. This transition occurred largely as a result of economic and technological changes made possible by the aggressively optimistic borrowing, investing and expansion that some farmers were willing to embrace in the latter half of the 20th century. Many other farmers, who had stared down economic catastrophe in the 1920s and '30s, were unwilling to take on new big risks, and their farms generally gave way to the forces favoring consolidation and the mass-production of agricultural commodities. (Watch an audio slide show about the book.)

Switzer's book is not a treatise on the evolution of American farming, however.

"The characters in this story are not statistical stick figures illustrating the decline of a Midwestern family farm," he writes. "They are my family. The details of their lives provide an intimate portrait of a once common way of life, now almost entirely vanished from the American countryside."

This portrait includes details normally left out of family memoirs: his maternal grandmother's hostility to her daughter's intellectual and educational aspirations; his grandfather's recurrent narcolepsy, a lifelong handicap brought on by severe heatstroke suffered while working in the fields as a teenager; Switzer's mother's depression and unhappiness with farm life; and his father's inability to recruit his sons to the profession.

The book also offers an account of the changes that occurred over the 76 years the family owned the farm, from the early days of kerosene lamps, hand milking and horse-drawn plows, to the gradual though never fully realized modernization of equipment and farming techniques.

Switzer begins with the gritty details of his grandparents' daily life. Charlie and Mabel Allison milked their cows twice daily in a drafty barn. They lived in an oversized and poorly insulated farmhouse with no modern conveniences. They grew corn, hay, oats and barley to feed their livestock and themselves. Charlie carted fresh milk to a nearby cheese factory every morning. Mabel kept a vegetable garden and orchard, and canned produce for the winter. The couple raised chickens and sold their eggs.

View original post here:
Memoir tracks the life, decline and death of a family farm

Research and Markets: Biophysics: A Physiological Approach

Posted on by

DUBLIN--(BUSINESS WIRE)--

Dublin - Research and Markets (http://www.researchandmarkets.com/research/6c8w7q/biophysics_a_phys) has announced the addition of the "Biophysics. A Physiological Approach" report to their offering.

Specifically tailored to life science students, this textbook explains quantitative aspects of human biophysics with examples drawn from contemporary physiology, genetics and nanobiology.

It outlines important physical ideas, equations and examples at the heart of contemporary physiology, along with the organization necessary to understand that knowledge.

The wide range of biophysical topics covered include energetics, bond formation and dissociation, diffusion and directed transport, muscle and connective tissue physics, fluid flow, membrane structure, electrical properties and transport, pharmacokinetics and system dynamics and stability.

Enabling students to understand the uses of quantitation in modern biology, equations are presented in the context of their application, rather than derivation. They are each directed toward the understanding of a biological principle, with a particular emphasis on human biology.

Key Topics Covered:

1. The energy around us

2. Molecular contacts

3. Diffusion and directed transport

More:
Research and Markets: Biophysics: A Physiological Approach

Practical Nutrition: Eating for two

Posted on by

If you've ever been pregnant, you may have thought "I feel fat!" While pregnant women become larger, they're growing a baby, not just packing on the pounds.

Weight gain associated with pregnancy has very real components. On average it's made up of about 7.5 pounds baby, 7 pounds maternal stores of protein, fat and other nutrients, 4 pounds extra blood, 4 pounds other body fluids, 2 pounds uterus growth, 2 pounds breast tissue, 1.5 pounds placenta, and 2 pounds amniotic fluid.

Healthy weight gain is based on pre-pregnancy weight and body mass index, or BMI. A woman who is underweight (BMI less than 18.5) would need to gain 28 to 40 pounds. Those at a healthy weight, BMI 18.5 to 24.9, should gain 25 to 35 pounds.

An overweight woman (BMI 25 to 29.9) should gain 15 to 25 pounds, but if she's obese (BMI higher than 30) only 11 to 20 pounds.

Women expecting twins or triplets may need to gain 35 to 55 pounds depending on their BMI.

To determine your BMI, go to http://www.nhlbisupport.com/bmi.

Unfortunately, many women take the old saying "eating for two" too seriously and gain extra weight. It can lead to health problems such as diabetes and high blood pressure during pregnancy. And it can be difficult to lose that extra weight after delivery, which can add up between pregnancies.

For most women, a mere 300 extra calories per day is all that's needed to achieve the desired weight.

Calcium is important for mom's bone health as well as the baby's. Select three to four servings of dairy products daily to meet these needs. One serving equals 8 ounces milk, 8 ounces yogurt, or 1.5 to 2 ounces of cheese.

Pregnant women need to consume iron-rich foods daily. Include enriched and fortified grains and cereal, red meats, liver, fish, chicken, dried beans, nuts, dried fruits and leafy green vegetables throughout the day.

View post:
Practical Nutrition: Eating for two

Schiff Nutrition International, Inc. to Change its NYSE Ticker Symbol to SHF

Posted on by

SALT LAKE CITY--(BUSINESS WIRE)--

Schiff Nutrition International, Inc., (WNI) is scheduled to change its NYSE ticker symbol and, effective June 11, the stock will begin trading under the symbol SHF.

Schiff has been nourishing life through nature and science for over 75 years, stated company CEO Tarang Amin. We are focused on building premium brands and leading innovation in heart health, joint care, immune support, digestive health and other key nutritional supplement conditions. We are excited to begin trading under a new ticker symbol NYSE: SHF that more closely reflects our company name.

The company was first listed on the New York Stock exchange in 1997 as Weider Nutrition International (WNI). In 2005, the company changed its name to Schiff Nutrition International.

About Schiff Nutrition

Schiff Nutrition International, Inc. is a leading nutritional supplement company offering vitamins, nutritional supplements and nutrition bars in the United States and abroad. Schiffs portfolio of well-known brands includes Move Free, MegaRed, Airborne, Tiger's Milk, Sustenex, Digestive Advantage and Schiff Vitamins. Focused on quality for 75 years, Schiffs headquarters and award-winning manufacturing and distribution facility are based in Salt Lake City, Utah. To learn more about Schiff, please visit the web site http://www.schiffnutrition.com.

See the article here:
Schiff Nutrition International, Inc. to Change its NYSE Ticker Symbol to SHF